Acceleron Pharma Inc.Company Review & Valuation

XLRN
Nasdaq
Latest Price
136.16USD
Market Capitalization
7.26bUSD

About Acceleron Pharma Inc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplasShow more tic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. Show less

Industry
Biotechnology
HQ Location
Cambridge, Massachusetts

Stock Price

Price data not available for Acceleron Pharma Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

back to top